BioDrugs

, Volume 19, Issue 5, pp 299–308 | Cite as

Mechanisms of Action for Treatments in Multiple Sclerosis

Does a Heterogeneous Disease Demand a Multi-Targeted Therapeutic Approach?
Mechanisms and Targets

Abstract

The etiology of multiple sclerosis (MS) is incompletely understood, and evidence suggests there may be more than one underlying cause in this disorder. Furthermore, this complex and heterogeneous autoimmune disease shows a high degree of clinical variability between patients. Therefore, in the absence of a single therapeutic target for MS, it is difficult to apply conventional drug design strategies in the search for new treatments. We review the potential mechanisms of action of several effective therapies for MS that are currently available or in development. The effects of each treatment are described in terms of their actions on key processes in a five-step model of MS pathogenesis. Conventional immunosuppressants targeting intracellular ligands (e.g. mitoxantrone) have broad cytotoxic effects on B cells, T cells, and macrophages. This suppresses the pathogenic immune response in MS with high efficacy but is also associated with high toxicity, limiting the long-term use of these agents. Monoclonal antibodies (e.g. natalizumab and alemtuzumab) are a new generation of immunosuppressants that act on immune-cell surface ligands. These agents have narrower immunosuppressive actions and different safety profiles compared with conventional immunosuppressants. Immunomodulators (interferon-β and glatiramer acetate), which shift the immune balance toward an anti-inflammatory response, are at the frontline of treatments for MS. Immunomodulators have targeted actions on the immune system, but affect a greater number of immunopathogenic processes than monoclonal antibodies. Given the inherent heterogeneity of MS, such treatments, which act at many levels of the disease, may achieve the best clinical results. Using our understanding of the interplay between mechanism of action and clinical effects in MS therapies may help us to better design and select new treatments for the future.

Keywords

Multiple Sclerosis Myelin Basic Protein Mitoxantrone Alemtuzumab Natalizumab 

Notes

Acknowledgments

This work was supported by Fonds national Suisse de la recherche, Alliance SEP, Genève, Switzerland. The author has no conflicts of interest directly relevant to the contents of this article.

References

  1. 1.
    Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707–17PubMedCrossRefGoogle Scholar
  2. 2.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907–11PubMedCrossRefGoogle Scholar
  3. 3.
    Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58(2): 169–78PubMedCrossRefGoogle Scholar
  4. 4.
    Neuhaus O, Archelos JJ, Hartung H-P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 2003; 24(3): 131–8PubMedCrossRefGoogle Scholar
  5. 5.
    PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. University of British Columbia MS/MRI Analysis Group. Neurology 2001; 56(12): 1628–36CrossRefGoogle Scholar
  6. 6.
    Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49(3): 290–7PubMedCrossRefGoogle Scholar
  7. 7.
    Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–25PubMedCrossRefGoogle Scholar
  8. 8.
    Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348(1): 15–23PubMedCrossRefGoogle Scholar
  9. 9.
    Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354(9191): 1691–5PubMedCrossRefGoogle Scholar
  10. 10.
    Rice GPA, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54: 1145–55PubMedCrossRefGoogle Scholar
  11. 11.
    Gonsette RE. New immunosuppressants with potential implication in multiple sclerosis. J Neurol Sci 2004; 223: 87–93PubMedCrossRefGoogle Scholar
  12. 12.
    Edan G, Morrissey S, Le Page E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35–9PubMedCrossRefGoogle Scholar
  13. 13.
    Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909–13PubMedCrossRefGoogle Scholar
  14. 14.
    Mittelbrunn M, Molina A, Escribese MM, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci U S A 2004; 101(30): 11058–63PubMedCrossRefGoogle Scholar
  15. 15.
    Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004; 63(12 Suppl. 6): S15–18PubMedCrossRefGoogle Scholar
  16. 16.
    Chan A, Weilbach FX, Toyka KV, et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152–8PubMedCrossRefGoogle Scholar
  17. 17.
    Ota K, Matsui M, Milford EL, et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183–7PubMedCrossRefGoogle Scholar
  18. 18.
    Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40: 1770–6PubMedCrossRefGoogle Scholar
  19. 19.
    Hartung H-P, Bar-Or A. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004; 251Suppl. 5: V12–29PubMedCrossRefGoogle Scholar
  20. 20.
    Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682–9PubMedCrossRefGoogle Scholar
  21. 21.
    Benczik M, Gaffen SL. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest 2004; 33(2): 109–42PubMedCrossRefGoogle Scholar
  22. 22.
    Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802–8PubMedCrossRefGoogle Scholar
  23. 23.
    Brown KA. Factors modifying the migration of lymphocytes across the blood-brain barrier. Int Immunopharmacol 2001; 1(12): 2043–62PubMedCrossRefGoogle Scholar
  24. 24.
    Correale J, Bassani Molinas Mde L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003; 140(1–2): 198–209PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang Y, Da R-R, Guo W, et al. Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients with multiple sclerosis. J Clin Immunol 2005; 25(3): 254–64PubMedCrossRefGoogle Scholar
  26. 26.
    Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005; 128: 1747–63PubMedCrossRefGoogle Scholar
  27. 27.
    Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106–12PubMedCrossRefGoogle Scholar
  28. 28.
    PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352(9139): 1498–504CrossRefGoogle Scholar
  29. 29.
    Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171(5): 2694–702PubMedGoogle Scholar
  30. 30.
    Huynh HK, Oger J, Dorovini-Zis K. Interferon-β downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995; 60: 63–73PubMedCrossRefGoogle Scholar
  31. 31.
    Miller A, Lanir N, Shapiro S, et al. Immunoregulatory effects of interferon-β and interacting cytokines on human vascular endothelial cells: implications for multiple sclerosis and other autoimmune diseases. J Neuroimmunol 1996; 64: 151–61PubMedCrossRefGoogle Scholar
  32. 32.
    Soilu-Hänninen M, Salmi A, Salonen R. Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995; 60: 99–106PubMedCrossRefGoogle Scholar
  33. 33.
    Schreiner B, Mitsdoerffer M, Kieseier BC, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004; 155: 172–82PubMedCrossRefGoogle Scholar
  34. 34.
    Giorelli M, Livrea P, Defazio G, et al. IFN-beta la modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. J Interferon Cytokine Res 2001; 21(10): 809–12PubMedCrossRefGoogle Scholar
  35. 35.
    Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-la in multiple sclerosis. J Immunol 2001; 112: 153–62Google Scholar
  36. 36.
    Genc K, Dona DL, Reder AT. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J Clin Invest 1997; 99: 2664–71PubMedCrossRefGoogle Scholar
  37. 37.
    Kawanokuchi J, Mizuno T, Kato H, et al. Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology 2004; 46(5): 734–42PubMedCrossRefGoogle Scholar
  38. 38.
    Shapiro S, Galboiz Y, Lahat N, et al. The ‘immunological-synapse’ at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-β. J Neuroimmunol 2003; 144: 116–24PubMedCrossRefGoogle Scholar
  39. 39.
    Sharief MK, Semra YK, Seidi OA, et al. Interferon-β therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 2001; 120: 199–207PubMedCrossRefGoogle Scholar
  40. 40.
    Ahn J, Feng X, Patel N, et al. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-β therapy: implications for control of apoptosis. Frontiers in Bioscience 2004; 9: 1547–55PubMedCrossRefGoogle Scholar
  41. 41.
    Billiau A, Kieseier BC, Hartung H-P. Biologic role of interferon beta in multiple sclerosis. J Neurol 2004; 251Suppl. 2: II/10–14Google Scholar
  42. 42.
    Zang YC, Skinner SM, Robinson RR, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler 2004; 10(5): 499–506PubMedCrossRefGoogle Scholar
  43. 43.
    Sega S, Wraber B, Mesec A, et al. IFN-beta la and IFN-beta 1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 2004; 106(3): 255–8PubMedCrossRefGoogle Scholar
  44. 44.
    Nagai T, Devergne O, Mueller TF, et al. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines. J Immunol 2003; 171(10): 5233–43PubMedGoogle Scholar
  45. 45.
    Maguire van Seventer J, Nagai T, VanSeventer GA. Interferon-β differentially regulates expression of the IL-12 family members p35, p40, pl9, and EB 13 in activated human dendritic cells. J Neuroimmunol 2002; 133: 60–71CrossRefGoogle Scholar
  46. 46.
    Hussien Y, Sanna A, Söderström M, et al. Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001; 121: 102–10PubMedCrossRefGoogle Scholar
  47. 47.
    Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421(6924): 744–8PubMedCrossRefGoogle Scholar
  48. 48.
    Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 2003; 24(4): 207–12PubMedCrossRefGoogle Scholar
  49. 49.
    Vandenbroeck K, Alloza I, Gadina M, et al. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol 2004; 56(2): 145–60PubMedCrossRefGoogle Scholar
  50. 50.
    Noronha A, Toscas A, Jensen MA. IFN-beta decreases T cell activation and IFN-gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145–54PubMedCrossRefGoogle Scholar
  51. 51.
    Iarlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interfer-on-β-1b. J Neuroimmunol 2000; 107(1): 100–7PubMedCrossRefGoogle Scholar
  52. 52.
    Zang YCQ, Haider JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-β. J Neuroimmunol 2001; 112(1-2): 174–80PubMedCrossRefGoogle Scholar
  53. 53.
    Lund BT, Ashikian N, Ta HQ, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 2004; 155(1–2): 161–71PubMedCrossRefGoogle Scholar
  54. 54.
    Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348(1): 68–72CrossRefGoogle Scholar
  55. 55.
    Muraro PA, Leist T, Biekekova B, et al. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000; 111(192): 186–94PubMedCrossRefGoogle Scholar
  56. 56.
    Muraro PA, Liberati L, Bonanni L, et al. Decreased integrin gene expression in patients with MS responding to interferon-β treatment. J Neuroimmunol 2004; 150: 123–31PubMedCrossRefGoogle Scholar
  57. 57.
    Jensen J, Krakauer M, Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta 1b. Cytokine 2005; 29(1): 24–30PubMedGoogle Scholar
  58. 58.
    Graber J, Zhan M, Ford D, et al. Inteferon-β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 2005; 161: 169–76PubMedCrossRefGoogle Scholar
  59. 59.
    Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999; 53: 1402–8PubMedCrossRefGoogle Scholar
  60. 60.
    Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997; 41: 669–74PubMedCrossRefGoogle Scholar
  61. 61.
    Calabresi PA, Pelfrey CM, Tranquill LR, et al. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49: 1111–6PubMedCrossRefGoogle Scholar
  62. 62.
    Kraus J, Bauer R, Chatzimanolis N, et al. Interferon-β1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol 2004; 251: 464–72PubMedCrossRefGoogle Scholar
  63. 63.
    Calabresi PA, Prat A, Biernacki K, et al. T lymphocytes conditioned with interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol 2001; 115(1–2): 161–7PubMedCrossRefGoogle Scholar
  64. 64.
    Matusevicius D, Kivisakk P, Navikas VV, et al. Influence of IFN-beta lb (Betafer-on) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur J Neurol 1998; 5(3): 265–75PubMedCrossRefGoogle Scholar
  65. 65.
    Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853–63PubMedCrossRefGoogle Scholar
  66. 66.
    Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846–52PubMedCrossRefGoogle Scholar
  67. 67.
    Ozenci V, Kouwenhoven M, Teleshova N, et al. Multiple sclerosis: pro-and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000; 108(1–2): 236–43PubMedCrossRefGoogle Scholar
  68. 68.
    Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001; 50: 443–51PubMedCrossRefGoogle Scholar
  69. 69.
    Kraus J, Ling AK, Hamm S, et al. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004; 56(2): 192–205PubMedCrossRefGoogle Scholar
  70. 70.
    Hua LL, Kim MO, Brosnan CF, et al. Modulation of astrocyte inducible nitric oxide synthase and cytokine expression by interferon beta is associated with induction and inhibition of interferon gamma-activated sequence binding activity. J Neurochem 2002; 83(5): 1120–8PubMedCrossRefGoogle Scholar
  71. 71.
    Lucas M, Sanchez-Solino O, Solano F, et al. Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis. Neurochem Int 1998; 33: 101–2PubMedCrossRefGoogle Scholar
  72. 72.
    Lucas M, Rodriguez MC, Gata JM, et al. Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients. Neurochem Int 2003; 42(1): 67–71PubMedCrossRefGoogle Scholar
  73. 73.
    Hong J, Tejada-Simon MV, Rivera VM, et al. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler 2002; 8: 237–42PubMedCrossRefGoogle Scholar
  74. 74.
    Alvarez-Lafuente R, De Las Heras V, Bartolome M, et al. Beta-interferon treatment reduces human herpesvirus-6 viral load in multiple sclerosis relapses but not in remission. Eur J Neurol 2004; 52(2): 87–91CrossRefGoogle Scholar
  75. 75.
    Boutros T, Croze E, Yong VW. Interferon-β is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997; 69: 939–46PubMedCrossRefGoogle Scholar
  76. 76.
    Plioplys AV, Massimini N. Alpha/beta interferon is a neuronal growth factor. Neuroimmunomodulation 1995; 2(1): 31–5PubMedCrossRefGoogle Scholar
  77. 77.
    Neuhaus O, Farina C, Wekerle H, et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702–8PubMedCrossRefGoogle Scholar
  78. 78.
    Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 5556: 1704–14CrossRefGoogle Scholar
  79. 79.
    Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2001; 2(7): 1149–65PubMedCrossRefGoogle Scholar
  80. 80.
    Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92(1–2): 113–21PubMedCrossRefGoogle Scholar
  81. 81.
    Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci 2000; 97(13): 7452–7PubMedCrossRefGoogle Scholar
  82. 82.
    Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967–76PubMedCrossRefGoogle Scholar
  83. 83.
    Allie R, Hu L, Mullen KM, et al. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol 2005; 62: 889–94PubMedCrossRefGoogle Scholar
  84. 84.
    Prat A, Biernacki K, Antel JP. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon-β and copolymer-1. J Autoimmun 2005; 24: 119–24PubMedCrossRefGoogle Scholar
  85. 85.
    Dabbert D, Rosner S, Kramer M, et al. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci Lett 2000; 289(3): 205–8PubMedCrossRefGoogle Scholar
  86. 86.
    Burns J, Littlefield K. Failure of copolymer I to inhibit the human T-cell response to myelin basic protein. Neurology 1991; 41(8): 1317–9PubMedCrossRefGoogle Scholar
  87. 87.
    Ziemssen T. Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. Adv Exp Med Biol 2004; 541: 111–34PubMedCrossRefGoogle Scholar
  88. 88.
    Ziemssen T, Kumpfel T, Klinkert WE, et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125 (Pt 11): 2381–91PubMedCrossRefGoogle Scholar
  89. 89.
    Neuhaus O. Multiple sclerosis: immunological effects of mitoxantrone in vitro reveal antigen-presenting cells as major targets [abstract]. Eur J Neurol 2002; 9Suppl. 2: 130Google Scholar
  90. 90.
    Fidler JM, DeJoy SQ, Gibbons JJ. Selective immunomodulation by the antineo-plastic agent mitoxantrone: I. Suppression of B lymphocyte function. J Immunol 1986; 137(2): 727–32PubMedGoogle Scholar
  91. 91.
    Gbadamosi J, Buhmann C, Tessmer W, et al. Effects of mitoxantrone on multiple sclerosis patients’ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003; 49: 137–41PubMedCrossRefGoogle Scholar
  92. 92.
    Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: unforseen consequences. N Eng J Med. Epub 2005 Jun 9Google Scholar
  93. 93.
    Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Eng J Med. Epub 2005 Jun 9Google Scholar
  94. 94.
    Langer-Gould A, Atlas SW, Bollen AW, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Eng J Med. Epub 2005 Jun 9Google Scholar
  95. 95.
    Van Assche G, van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Eng J Med. Epub 2005 Jun 9Google Scholar
  96. 96.
    Goldblum R, Messersmith E, Freedman S, et al. Mechanism of action (MOA) of natalizumab in inflammatory conditions [presentation nr 764; poster board nr 144]. American College of Rheumatology 68th Annual Scientific Meeting; 2004 Oct 16–21; Texas [online]. Available from URL: http://www.abstractsonline.com [Accessed 2005 Aug 19]
  97. 97.
    Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466–72PubMedCrossRefGoogle Scholar
  98. 98.
    Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110(6): 673–87PubMedCrossRefGoogle Scholar
  99. 99.
    Qian F, Vaux DL, Weissman IL. Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 1994, 77335Google Scholar
  100. 100.
    Zhu Z, Sanchez-Sweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001; 61: 1707–16PubMedGoogle Scholar
  101. 101.
    Biogen Idec. Tysabri® (natalizumab) prescribing information 2004 [online]. Available from URL: http://www.fda.gov/cder/foi/label/2004/1251041bl.pdf [Accessed 2005 Aug 19]
  102. 102.
    Moreau T, Coles A, Wing M, et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1996; 1: 357–65PubMedGoogle Scholar
  103. 103.
    Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody campath 1H. Neurology 1999; 53: 751–7PubMedCrossRefGoogle Scholar
  104. 104.
    Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119: 225–37PubMedCrossRefGoogle Scholar
  105. 105.
    Bieber AJ, Kerr S, Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol 2003; 53(5): 680–4PubMedCrossRefGoogle Scholar
  106. 106.
    Bjartmar C, Trapp BD. Azonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003; 5(1-2): 157–64PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Neurology Department>Hôpitaux Universitaires de GenéeveGeneva 14Switzerland

Personalised recommendations